Novel drugs with potential activity in patients harboring tumors whose AR-related alterations are resistant to current ARSI, but can be targetable with these new agents, offer an exceptional opportunity to continue with androgen inhibition and, hopefully, survival contribution to patients with metastatic prostate cancer. This evidence concerns the gene AR and metastatic prostate carcinoma.